Business Context and Reporting Period
Company: Aastrom Biosciences, Inc. (Note: Input metadata referenced "Vericel Corp," but the filing text identifies the registrant as Aastrom Biosciences, Inc.)
Filing Type: Form 10-K (Annual Report)
Period Ended: June 30, 2010
Business Overview: Aastrom is a regenerative medicine company developing autologous cell therapies for severe, chronic cardiovascular diseases, specifically Critical Limb Ischemia (CLI) and Dilated Cardiomyopathy (DCM). The company utilizes a proprietary "single-pass perfusion" technology to expand stem and progenitor cells from patient bone marrow. As of the reporting date, the company is in the clinical development stage and has not achieved profitability.
Key Financial Metrics
| Metric (in thousands) | 2010 | 2009 | 2008 |
|---|---|---|---|
| Total Revenues | $89 | $182 | $522 |
| Net Loss | $(17,729) | $(15,946) | $(20,133) |
| Net Loss Per Share (Basic/Diluted) | $(0.72) | $(0.89) | $(1.25) |
| Cash, Cash Equivalents & Short-Term Investments | $19,119 | $17,000 | $22,462 |
| Working Capital | $16,857 | $16,104 | $21,963 |
| Long-Term Debt | $79 | $305 | $784 |
| Accumulated Deficit | $(213,552) | $(195,823) | $(179,877) |
Revenue Composition (2010): Product sales and rentals ($89,000). No grant revenues were recorded in 2010 or 2009.
Expense Breakdown (2010): Research and Development ($12,658,000); Selling, General and Administrative ($5,201,000); Cost of Product Sales ($34,000).
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased 51% from $182,000 in 2009 to $89,000 in 2010. This was driven by a decline in the volume of cell production sales for investigator-sponsored clinical trials in Spain and limited sales of manufacturing supplies.
- Increased Operating Expenses: Total costs and expenses increased 9% to $17.9 million in 2010 from $16.4 million in 2009. This increase was primarily due to higher clinical activity costs associated with the DCM and CLI programs.
- Net Loss Increase: Net loss increased to $17.7 million in 2010 from $15.9 million in 2009, reflecting the revenue decline and increased R&D spending.
- Liquidity Improvement: Cash and short-term investments increased by $2.1 million to $19.1 million, bolstered by a $12.4 million equity offering in January 2010 and $5.1 million in proceeds from the Fusion Capital purchase agreement.
Guidance, Outlook, and Risks
Clinical Outlook:
- CLI Program: Phase 2b RESTORE-CLI trial interim analysis (June 2010) showed statistically significant improvement in amputation-free survival (p=0.038) and time to treatment failure (p=0.0053). The company expects to advance to Phase 3 development in 2011.
- DCM Program: Phase 2 IMPACT-DCM surgical trial enrollment completed in January 2010. A catheter-based Phase 2 trial (Catheter-DCM) began enrollment in April 2010.
Capital Resources: Management believes cash on hand ($19.1 million) is adequate to finance operations through June 30, 2011. However, significant additional funding will be required to complete clinical trials and commercialize products. The company has a $30 million common stock purchase agreement with Fusion Capital Fund II, LLC, under which it can sell shares as needed, subject to stock price conditions.
Key Risks:
- Profitability: The company has never been profitable and expects to incur losses for the foreseeable future.
- Regulatory Approval: Products require FDA approval via a Biologics License Application (BLA). There is no assurance of approval or timing.
- Supply Chain: Reliance on third-party suppliers for critical manufacturing components (e.g., cell culture cassettes). A key supplier, Moll Industries, filed for bankruptcy in April 2010, requiring a transition to a new supplier (ATEK Medical).
- Intellectual Property: Reliance on licenses from the University of Michigan; first underlying patent expires in March 2012.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $19.1 million cash balance to fund operations through mid-2011 without further dilution.
- Phase 3 Readiness: Confirm the timeline and FDA agreement (Special Protocol Assessment) for the CLI Phase 3 trial planned for 2011.
- Supplier Transition: Assess the status of the transition from Moll Industries to ATEK Medical for cell culture cassettes and any potential impact on clinical trial timelines.
- Financing Terms: Review the specific conditions of the Fusion Capital purchase agreement, particularly the stock price floors ($0.80 and $2.88) that could limit access to capital.
- Patent Expiry: Evaluate the impact of the University of Michigan patent expiring in March 2012 on the company's competitive moat.